ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?

Muhammad Muntazir Mehdi Khan; Casey J. Allen

doi:10.1245/s10434-026-19700-3

Back

ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?

Editorial

Open access

Peer reviewed

ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?

Muhammad Muntazir Mehdi Khan and Casey J. Allen

Annals of surgical oncology

21 Apr 2026

DOI: https://doi.org/10.1245/s10434-026-19700-3

PMID: 42012739

Files and links (1)

url

https://doi.org/10.1245/s10434-026-19700-3View

Published, Version of Record (VoR) Open Maybe Open Access (Publisher Bronze)

Abstract

Life Sciences & Biomedicine

Science & Technology

Oncology

Surgery

Although the benefits of perioperative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) are well established, the role of adjuvant radiotherapy (adjXRT) following pancreaticoduodenectomy (PD) remains controversial. While the NCCN provides guidance regarding the use of adjXRT based on margin status, there is conflicting evidence supporting its role in nodal disease (N+) alone. [1st paragraph]

Metrics

1 Record Views

Details

Title: ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?
Creators: Muhammad Muntazir Mehdi Khan - Allegheny Health Network
Casey J. Allen - Drexel University, Surgery
Publication Details: Annals of surgical oncology
Publisher: Springer Nature
Number of pages: 1
Resource Type: Editorial
Language: English
Academic Unit: Surgery
Web of Science ID: WOS:001745372600001
Scopus ID: 2-s2.0-105036486908
Other Identifier: 991022181972104721

ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?

Files and links (1)

Abstract

Metrics

Details

Drexel University Social media